Program
mRNA COVID-19 Vaccine
Also written as “COVID-19 mRNA vaccine”, “COVID-19 mRNA Vaccine (ZSVG-02-O)” and “COVID-19 mRNA Vaccine (nucleoside modified)”.
Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections · Influenza, Human · Severe Acute Respiratory Syndrome, led by 10 companies.
Drug pageMRNA COVID-19 Vaccine: every studyMany companies study it; this page follows only the 13 they lead. All 18 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CanSino Biologicsits history only | 20 open or running | phase 2since May 12, 2022 | May 12, 2022 | none ahead |
| CNBG-Virogin Biotech (Shanghai)its history only | 22 open or running | phase 2since Oct 31, 2023 | Oct 31, 2023 | none ahead |
| Sanofiits history only | 20 open or running | phase 2since Mar 11, 2021 | Mar 11, 2021 | none ahead |
| Argorna Pharmaceuticalsits history only | 10 open or running | phase 1since May 28, 2023 | May 28, 2023 | none ahead |
| Bayerits history only | 10 open or running | phase 3since Apr 16, 2021 | Apr 16, 2021 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Apr 16, 2024 | Apr 16, 2024 | none ahead |
| Invivydits history only | 10 open or running | phase 3since Jun 8, 2026 | Jun 8, 2026 | none ahead |
| Stemirna Therapeuticsits history only | 10 open or running | phase 2since Nov 11, 2021 | Nov 11, 2021 | none ahead |
| Vaccineits history only | 10 open or running | phase 1since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Walvax Biotechnologyits history only | 10 open or running | phase 3since Apr 13, 2021 | Apr 13, 2021 | none ahead |
Also a collaborator on its studies: Abogen Biosciences and BioNTech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2021First study: phase 2 study in COVID-19New to SanofiSanofi · NCT04798027 · 182 enrolled · United States, Australia, Brazil and more
- Apr 13, 2021Walvax Biotechnology’s first study: phase 3 study in COVID-19New to Walvax BiotechnologyWalvax Biotechnology · NCT04847102 · 28,000 enrolled · Indonesia, Mexico
- Apr 16, 2021Bayer’s first study: phase 3 study in COVID-19New to BayerBayer · NCT04848467
- Jul 16, 2021Phase 2 study in Influenza, HumanSanofi · NCT04969276 · 306 enrolled · United States
- Nov 11, 2021Stemirna Therapeutics’ first study: phase 2 study in COVID-19New to Stemirna TherapeuticsStemirna Therapeutics · NCT05144139 · 480 enrolled · Lao People's Democratic Republic
- May 12, 2022CanSino Biologics’ first study: phase 1 study in COVID-19New to CanSino BiologicsCanSino Biologics · NCT05373485 · 43 enrolled · China
- May 12, 2022Phase 2 study in COVID-19CanSino Biologics · NCT05373472 · 150 enrolled · China
- May 28, 2023Argorna Pharmaceuticals’ first study: phase 1 study in SARS-CoV-2New to Argorna PharmaceuticalsArgorna Pharmaceuticals · NCT05897190 · 60 enrolled · China
- Jul 5, 2023Vaccine’s first study: phase 1 study in Severe Acute Respiratory SyndromeNew to VaccineVaccine · NCT05938075 · 130 enrolled · South Africa
- Oct 31, 2023CNBG-Virogin Biotech (Shanghai)’s first study: phase 1 study in COVID-19New to CNBG-Virogin Biotech (Shanghai)CNBG-Virogin Biotech (Shanghai) · NCT06113744 · 164 planned · China
- Oct 31, 2023Phase 2 study in COVID-19CNBG-Virogin Biotech (Shanghai) · NCT06113731 · 980 planned · China
- Apr 16, 2024GlaxoSmithKline’s first study: phase 3 study in Respiratory Syncytial Virus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT06374394 · 841 enrolled · United States, Belgium, Netherlands and more
- Jun 8, 2026Invivyd’s first study: phase 3 study in COVID-19New to InvivydInvivyd · NCT07655180 · 210 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“mRNA COVID-19 Vaccine”name, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07655180COVID-19 · United States | 3 | Completed | Invivyd | Aug 15, 2026 | 210 |
| NCT06374394Respiratory Syncytial Virus Infections · United States, Belgium, Netherlands and more | 3 | Completed | GlaxoSmithKline | Nov 1, 2024 | 841 |
| NCT06113744COVID-19 · China | 1 | Recruiting | CNBG-Virogin Biotech (Shanghai) | Jun 30, 2023 | 164 |
| NCT06113731COVID-19 · China | 2 | Recruiting | CNBG-Virogin Biotech (Shanghai) | Oct 30, 2023 | 980 |
| NCT05938075Severe Acute Respiratory Syndrome · South Africa | 1 | Completed | Vaccine | Jul 25, 2024 | 130 |
| NCT05897190SARS-CoV-2 · China | 1 | Completed | Argorna Pharmaceuticals | Jun 13, 2022 | 60 |
| NCT05373485COVID-19 · China | 1 | Completed | CanSino Biologics | Aug 8, 2022 | 43 |
| NCT05373472COVID-19 · China | 2 | Completed | CanSino Biologics | Sep 21, 2022 | 150 |
| NCT05144139COVID-19 · Lao People's Democratic Republic | 2 | Completed | Stemirna Therapeutics | Aug 28, 2022 | 480 |
| NCT04969276Influenza, Human · United States | 2 | Completed | Sanofi | Feb 8, 2022 | 306 |
| NCT04848467COVID-19 | 3 | Withdrawn | Bayer | Nov 30, 2021 | 0 |
| NCT04847102COVID-19 · Indonesia, Mexico | 3 | UNKNOWN | Walvax Biotechnology | Nov 30, 2021 | 28,000 |
| NCT04798027COVID-19 · United States, Australia, Brazil and more | 2 | Terminated | Sanofi | Jun 27, 2022 | 182 |
How it is read
Names in the registry
- “COVID-19 mRNA vaccine”, 6 entries
- “COVID-19 mRNA Vaccine (ZSVG-02-O)”, 2 entries
- “COVID-19 mRNA Vaccine (nucleoside modified)”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 1”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 2”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 9 studies
- Respiratory Syncytial Virus Infections, 1 study
- Influenza, Human, 1 study
- Severe Acute Respiratory Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.